Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 10/2014

01-10-2014 | Research Article

Lung cancer risk in relation to TP53 codon 47 and codon 72 polymorphism in Bangladeshi population

Authors: Md. Shaki Mostaid, Maizbha Uddin Ahmed, Mohammad Safiqul Islam, Muhammad Shahdaat Bin Sayeed, Abul Hasnat

Published in: Tumor Biology | Issue 10/2014

Login to get access

Abstract

The objective of this study was to determine whether p53 codon 47 and codon 72 polymorphisms are associated with increased risk of lung cancer in Bangladeshi population. We carried out a case-control study and examined the genotype distribution Pro47Ser and Arg72Pro single-nucleotide polymorphisms along with tobacco smoking in the predisposition of lung cancer by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) approach. The study included 106 lung cancer patients and 116 control subjects from Bangladesh. Lung cancer risk was estimated as odds ratio (OR) and 95 % confidence interval (CI) using conditional logistic regression models adjusting for age, sex, and smoking. No significant association was found between Pro47Ser SNP and lung cancer. The frequencies of p53 codon 72 polymorphisms (Arg/Arg, Arg/Pro, and Pro/Pro) in lung cancer were 25.5, 37.7, and 36.8 %, respectively; frequencies in the controls were 53.4, 30.2, and 16.4 %, respectively (p < 0.01). The Arg/Pro and Pro/Pro genotype were significantly associated with increased risk of lung cancer (OR = 2.51, 95 % CI = 1.38–4.82 and OR = 4.62, 95 % CI = 2.31–9.52, respectively) compared with the Arg/Arg genotype. The combined frequency of Arg/pro and Pro/Pro genotype was also found to be associated with elevated risk of lung cancer (OR = 3.36, 95 % CI = 1.90–5.94, p < 0.01). However, no significant relationship was found between age, sex, and histological subtypes of lung cancer with p53 codon 72 genotype distributions. When classified by smoking status, the effects of Arg72Pro polymorphism on lung cancer risk was only found to be significant (χ 2  = 33.94, p = 0.00000004) in case of heavy smokers (40 packs per year or more). We conclude that not Pro47Ser SNP but Arg72Pro SNP is involved in susceptibility to developing lung cancer, at least in Bangladeshi population.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statstics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMed
2.
Hirsch FR, Franklin WA, Gazdar AF, Bunn Jr PA. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res. 2001;7:5–22.PubMed
3.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. Lyon, France: International Agency for Research on Cancer. 2010. Available from: http://​globocan.​iarc.​fr; last accessed: August 1, 2013.
4.
Sato M, Shames DS, Gazdar AF, et al. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol. 2007;2(4):327–43.CrossRefPubMed
5.
Stewart BW, Kleihues P, editors. World cancer report. Lyon: IARC Press; 2003.
6.
Koo LC, Hoo JH. Worlwide epidemiological patterns of lung cancer in nonsmokers. Int J Epidemiol. 1990;19:14–23.CrossRef
7.
Tang L, Zirpol GR, Jayaprakash V, et al. Cruciferous vegetable intake is inversely associated with lung cancer risk among smokers: a case control study. BMC Cancer. 2010;10:162.CrossRefPubMedPubMedCentral
8.
Alexandrie AK, Sundberg MI, Seidegard J. Genetic susceptibility to lung cancer with susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis. 1994;15:1785–90.CrossRefPubMed
9.
10.
Matakidou A, Eisen T, Houlston RS. TP53 polymorphisms and lung cancer risk: a systemic review and meta-analysis. Mutagenesis. 2003;18:377–85.CrossRefPubMed
11.
12.
Borjesen SE, Nordestgaard BG. The common germline Arg72Pro polymorphism of p53 and increased longevity in humans. Cell Cycle. 2008;7:158–63.CrossRef
13.
Viallet J, Minna JD. Dominant oncogenes and tumor suppressor genes in the pathogenesis of lung cancer. Am J Respir Cell Mol Biol. 1990;2:225–32.CrossRefPubMed
14.
Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9:95–107.CrossRefPubMed
15.
16.
Vousden KH, Lane DP. p53 in health and disease. Nature Rev Mol Cell Biol. 2007;8:275–83.CrossRef
17.
Spitz MR, Wei Q, Li G, et al. Genetic susceptibility to tobacco carcinogenesis. Cancer Invest. 1999;17:661–2.CrossRef
18.
Takahashi T, Suzuki H, Hida T, et al. The p53 gene is very frequently mutated in small cell lung cancer with a distinct nucleotide substitution pattern. Oncogene. 1991;6:1775–8.PubMed
19.
Ahuja HG, Testa MP, Cline MJ. Variation in the protein coding region of the p53 gene. Oncogene. 1990;5:1409–10.PubMed
20.
Felix CA, Brown DL, Mitsudomi T, Ikagaki N, Wong A, Wasserman R, et al. Polymorphism at codon 36 of the p53 gene. Oncogene. 1994;9(1):327–8.PubMed
21.
Felley-Bosco E, Weston A, Cawley HM, Bennett WP, Harris CC. Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am J Hum Genet. 1993;53:752–9.PubMedPubMedCentral
22.
Harris N, Brill E, Shohat O, Prokocimer M, Wolf D, Arai N, et al. Molecular basis for heterogenecity of the human p53 protein. Mol Cell Biol. 1986;6:4650–6.CrossRefPubMedPubMedCentral
23.
Weston A, Perrin LS, Forrester K, et al. Allelic frequency of a p53 polymorphism in human lung cancer. Cancer Epidemiol Biomarkers Prev. 1992;1:481–3.PubMed
24.
Carbone D, Chiba I, Mitsudomi T. Polymorphism at codon 213 within the p53 gene. Oncogene. 1991;6:1691–2.PubMed
25.
Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 2002;21(48):7435–51.CrossRefPubMed
26.
27.
28.
Beckman G, Birgander R, Sjalander A, Saha N, et al. Is p53 polymorphism maintained by natural selection? Hum Hered. 1994;44:266–70.CrossRefPubMed
29.
Zhang XM, Miao X, Guo Y, et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat. 2006;7:110–7.CrossRef
30.
Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998;393:229–34.CrossRefPubMed
31.
Murata M, Tagawa M, Kimura H, et al. Correlation of the mutation of p53 gene and the polymorphism at codon 72 in smoking-relaed non-small cell lung cancer patients. Int J Oncol. 1998;12:577–81.PubMed
32.
Peller S, Halperin R, Scheneider D, et al. Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma. Oncol Rep. 1999;6:193–7.PubMed
33.
Wang YC, Lee HS, Chen SK, et al. Prognostic significance of p53 codon 72 polymorphism in lung carcinomas. Eur J Cancer. 1999;35:226–30.CrossRefPubMed
34.
Makni H, Franco EL, Kaiano J, et al. P53 polymorphisms in codon 72 and risk of human papilloma virus-induced cervical cancer: effect of inter laboratory variation. Int J Cancer. 2000;87:528–33.CrossRefPubMed
35.
Zehbe I, Voglino G, Willander E, et al. p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors fopr cervical cancer development. Cancer Res. 2001;61:608–11.PubMed
36.
Helland A, Langerod A, Johnsen H, et al. p53 polymorphism and risk of cervical cancer. Nature. 1998;396:530–1.CrossRefPubMed
37.
Hildesheim A, Schiffman M, Brinton LA, et al. p53 polymorphism and risk of cervical cancer. Nature. 1998;396:531–2.CrossRefPubMed
38.
Josefsson AM, Magnusson PK, Yliatilo N, Magnusson P, Quarforth-Tubbin P, Ponten J, et al. p53 polymorphism and risk of cervical cancer. Nature. 1998;396:531–2.CrossRefPubMed
39.
Zhou C, Chen H, Wang A. P53 codon 72 polymorphism and lung cancer risk: evidence from 27,958 subjects. Tumor Biol. 2013;34(5):2961–9.CrossRef
40.
Chua W, Nq D, Choo S, et al. Effect of MDM2 SNP 309 and p53 codon 72 polymorphism on lung cancer risk and survival among non-smoking Chienese women inSingapore. BMC Cancer. 2010;10:88.CrossRefPubMedPubMedCentral
41.
Hancox RJ, Poulton R, Welch D, et al. Accelerated decline on lung fuction in cigeratte smokers is associated with TP53/MDM2 polymorphism. Hum Genet. 2009;126(4):559–65.CrossRefPubMedPubMedCentral
42.
Qiao Q, Hu W. The association between TP53 Arg72Pro polymorphism and luncer susceptibility: evidence from 30,038 subjects. Lung. 2013;191(4):369–77.CrossRefPubMed
43.
Kiyohara C, Horiuchi T, Miyake Y, et al. Cigarette smoking, TP53 Arg72Pro, TP53BP1 Asp353Glu and the risk of lung cancer in a Japanese population. Oncol Rep. 2010;23(5):1361–8.CrossRefPubMed
44.
Wang S, Lan X, Tan S, et al. P53 codon 72 Arg/Pro polymorphism and lung cancer risk in asians: an updated meta analysis. Tumor Biol. 2013;34(5):2511–20.CrossRef
45.
Liu D, Wang F, Guo X, et al. Association between P53 codon 72 genetic polymorphisms and tobacco use and lung cancer risk in Chinese population. Mol Biol Rep. 2013;40(1):645–9.CrossRefPubMed
46.
Caceres DD, Quinones LA, Schroeder JC, et al. Association between P53 codon72 genetic polymorphism and tobacco use and lung cancer risk. Lung. 2009;187(2):110–5.CrossRefPubMed
47.
Ye XH, Bu ZB, Feng J, et al. Association between the TP53 polymorphisms and lung cancer risk: a meta analysis. Mol Biol Rep. 2014;41(4):373–85.CrossRefPubMed
48.
Papadakis ED, Soulitzis L, Spandidos DA. Association of p53 codon 72 polytmorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer. 2002;87:1013–8.CrossRefPubMedPubMedCentral
49.
Kawajiri K, Nakachi K, Imai K, et al. Germline polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis. 1993;14:1085–9.CrossRefPubMed
50.
Birgander R, Sjalander A, Rannug A, et al. P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis. 1995;16:2233–6.CrossRefPubMed
51.
To-Figueras J, Gene M, Gomez-Catalan J, et al. Glutathione-S-Transferase M1 and codon 72 p53 polymorphisms in a northwestern Mediterranean population and their relation to lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 1996;5:337–42.PubMed
52.
Pierce LM, Sivaraman L, Chang W, et al. Relationships of TP53 codon 72 and HRAS1 polymorphisms with lung cancer risk in an ethnically divesre population. Cancer Epidemiol Biomarkers Prev. 2000;9:1199–204.PubMed
53.
Ignaszak-Szczepaniak M, Horst-Sikorska W, Sawicka J, Kaczmarek M, et al. The TP53 codon 72 polymorphism and predisposition to adrenocortical cancer in Polish patients. Oncol Rep. 2006;16:65–71.PubMed
54.
Dumont P, Leu JI, Della Pietra AC, George DL, et al. The codon 72 polymorphic variants of p53have markedly different apoptotic potential. Nat Genet. 2003;33:357–65.CrossRefPubMed
55.
Tagawa M, Murata M, Kimura H. Prognostic value of mutations and a germ line polymorphism of the p53 gene in non-small cell lung carcinoma: association with clinicopathological features. Cancer Lett. 1998;128:93–9.CrossRefPubMed
56.
Li X, Dumont P, Della PA, Shelter C, et al. The codon 47 polymorphism in p53 is functionally significant. J Biol Chem. 2005;280:24245–51.CrossRefPubMed
57.
58.
Sreeja L, Syamala V, Raveendran PB, et al. p53 Arg72Pro polymorphism predicts survival outcome in lung cancer patients in Indian population. Cancer Invest. 2008;26:41–6.CrossRefPubMed
59.
Jain N, Singh V, Hedau S, et al. Infection of human papillomavirus type 18 and p53 codon 72 polymorphism in lung cancer patients from India. Chest. 2005;128:3999–4007.CrossRefPubMed
60.
61.
62.
Daly AK, Monkman SC, Smart J, Steward A, Choletron S. Analysis of cytochrome P450 polymorphisms. Meth Mol Biol. 1998;107:405–22.
63.
Chattopadhyay P, Pathore A, Mathur M, et al. Loss of heterozygosity of a locus on 17p13.3, independent of p53, is associated with higher grades of astrocytic tumours. Oncogene. 1997;15:871–4.CrossRefPubMed
64.
Pinto GR, Yoshioka FK, Silva RL, et al. Prognostic value o TP53 Pro47Ser and Arg72Pro single nucleotide polymorphiosms nad the susceptibility to gliomas in individuals from southeast Brazil. Genet Mol Res. 2008;7:207–2016.CrossRefPubMed
65.
Vogelstein B, Kinzler K. Cancer genes and the pathways they control. Nature. 2004;10(8):789–99.
66.
Lengaurer C, Kinzler K, Vogelstein B. Genetic instabilities in human cancer. Nature. 1998;396:643–9.CrossRef
67.
Costa S, Pinto D, Pereira D, et al. Importance of TP53 codon 72 and intron 3 duplication 16 bp polymorphisms in prediction susceptibility on breast cancer. BMC Cancer. 2008;8:32.CrossRefPubMedPubMedCentral
68.
Sjalander A, Birgander R, Hallmans G, et al. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis. 1996;17:1313–6.CrossRefPubMed
69.
Thomas M, Kalita A, Labrecque S, et al. Two polymorphic variants of wild type p53 differ biochemically and bilogically. Mol Cell Biol. 1999;19:1092–100.CrossRefPubMedPubMedCentral
70.
Lee JM, Lee YC, Yang SY, et al. Genetic polymorphisms of p53 and GSTP1, but not NAT2, are associated with susceptibility to squmaous-cell carcinoma of the esophagus. Int J Cancer. 2000;89:458–64.CrossRefPubMed
71.
Hiyama T, Tanaka S, Kitadai Y, et al. p53 codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter Pylori associated chronic gastritis. Int J Cancer. 2002;100:304–8.CrossRefPubMed
72.
Irarrazabal CE, Rojas C, Aracena C, et al. Chilean pilot study on the risk of lung cancer associated with codon 72 polymorphism in the gene of protein p53. Toxicol Lett. 2003;144:69–76.CrossRefPubMed
73.
Zhu ZZ, Wang AZ, Jia HR, Jin XX. Association of the TP53 codon 72 polymorphism with colorectal cancer in Chinese population. Jpn J Clin Oncol. 2007;37:385–90.CrossRefPubMed
74.
Jin X, Wu X, Roth JA. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis. 1995;16:2205–8.CrossRefPubMed
75.
Fan R, Wu MT, Miller D, et al. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers prev. 2000;9:1037–42.PubMed
76.
Miller DP, Liu G, Vivo ID. Combinations of the variants of GSTP1, GSTM1, and p53 are associated with an increased lung cancere risk. Cancer Res. 2002;62:2819–23.PubMed
77.
Yan L, Zhang D, Chen C, et al. TP53 Arg72Pro polymorphism and lung cancer risk: a meta-alalysis. Int J Cancer. 2009;125:2903–11.CrossRefPubMed
78.
Piao JM, Kim HN, Song HR, et al. p53 codon 72 polymorphism and the risk of lung cancer in a Korean population. Lung Cancer. 2011;73:264–7.CrossRefPubMed
79.
Bergamaschi G, Merante S, Orlandi E, et al. TP53 codon 72 polymorphism in patients with chronic myleoid leukemia. Haematologica. 2004;89:868–9.PubMed
80.
Sakiyama T, Kohno T, Mimaki S, et al. Association of amino acid substitution polymorphism in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk. Int J Cancer. 2005;114:730–7.CrossRefPubMed
81.
Fernandez-Rubio A, Lopez-Cima MF, Gonzalez-Arriaga P, et al. The TP53 Arg72Pro polymorphism and lung cancer risk in a population of Northern Spain. Lung Cancer. 2008;61:309–16.CrossRefPubMed
Metadata
Title
Lung cancer risk in relation to TP53 codon 47 and codon 72 polymorphism in Bangladeshi population
Authors
Md. Shaki Mostaid
Maizbha Uddin Ahmed
Mohammad Safiqul Islam
Muhammad Shahdaat Bin Sayeed
Abul Hasnat
Publication date
01-10-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 10/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2285-2

Other articles of this Issue 10/2014

Tumor Biology 10/2014 Go to the issue

Research Article

Increased EphB2 expression predicts cholangiocarcinoma metastasis

Research Article

BMP-7 blocks the effects of TGF-β-induced EMT in cholangiocarcinoma

Research Article

Adhesion to type V collagen enhances staurosporine-induced apoptosis of adrenocortical cancer cells

Review

Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review

Review

The lncRNA-MYC regulatory network in cancer

Research Article

Expression of metabolism-related proteins in invasive lobular carcinoma: comparison to invasive ductal carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits